Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.
The FDA has recently approved two new prophylactic treatments for people with hemophilia who develop antibodies to clotting ...
A bankruptcy court in Texas rejected J&J’s proposed bankruptcy plan to settle claims related to its talc lawsuits for the third time. In September, J&J, via a subsidiary called Red River Talc, filed ...
GlobalData on MSN13h
FDA awards ODD status to Sanofi’s rilzabrutinib for two rare conditionsSanofi's reversible BTK inhibitor rilzabrutinib has gained the US Food and Drug Administration’s (FDA) orphan drug ...
Zacks Investment Research on MSN8h
Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits FailureThis week, the FDA approved Sanofi’s SNY hemophilia therapy, fitusiran, Novartis’ NVS Vanrafia for the reduction of ...
In a report released yesterday, Whitney Ijem from Canaccord Genuity reiterated a Buy rating on Alnylam Pharma (ALNY – Research Report), with a ...
More than 70% of dementia diagnoses are for Alzheimers’s. Credit: via Shutterstock. Dementia affects millions of people worldwide, causing a serious impact on the economy and the healthcare system.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback